ERBB2 and triple-negative breast carcinoma: A separate set of subtyping criteria relies on the expression of important therapeutic markers: estrogen receptor (ER), progesterone receptor (PR), and HER-2, from which the term triple negative breast cancer (TNBC) is derived.